3.00

3.54% -0.11

After Hours: 3.01 0.010 +0.33%

Kyverna Therapeutics Inc (KYTX)

Overview News Price History Discussions Forecast

Kyverna Therapeutics Inc stock is traded at $3.00, with a volume of 176.00K. It is down -3.54% in the last 24 hours and down -22.28% over the past month. Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Previous Close:

$3.11

Open:

$3.1

24h Volume:

176.00K

Relative Volume:

0.47

Market Cap:

$130.81M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-7.41%

1M Performance:

-22.28%

6M Performance:

-57.02%

1Y Performance:

+0.00%

1-Day Range:

$3.00

$3.11

1-Week Range:

$3.00

$3.40

52-Week Range:

$3.00

$30.60

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Name

Kyverna Therapeutics Inc

Sector

Healthcare (1183)

Industry

Biotechnology (679)

Phone

(510) 626-8331

Address

5980 HORTON STREET, EMERYVILLE

Employee

119

Twitter

Next Earnings Date

Latest SEC Filings

KYTX's Discussions on Twitter

Compare KYTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYTX Kyverna Therapeutics Inc	3.00	130.81M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	469.23	122.13B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	710.00	78.30B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	646.64	39.73B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	276.19	35.50B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.61	28.47B	3.30B	-501.07M	1.03B	-2.1146

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-24	Initiated	UBS	Buy
Oct-09-24	Initiated	Rodman & Renshaw	Buy
Jul-03-24	Initiated	H.C. Wainwright	Neutral
Mar-04-24	Initiated	JP Morgan	Overweight
Mar-04-24	Initiated	Leerink Partners	Outperform
Mar-04-24	Initiated	Morgan Stanley	Overweight
Mar-04-24	Initiated	Wells Fargo	Overweight

View All

Kyverna Therapeutics Inc Stock (KYTX) Latest News

11:42 AM

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PR Newswire

11:42 AM

11:05 AM

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - PR Newswire

11:05 AM

05:45 AM

Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire

05:45 AM

Feb 06, 2025

The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire

Feb 06, 2025

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX - GlobeNewswire Inc.

Feb 06, 2025

KYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors - The Bakersfield Californian

Feb 06, 2025

Feb 05, 2025

Deadline Soon: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire

Feb 05, 2025

Feb 04, 2025

Kyverna Therapeutics, Inc. Investors: Please contact the - GlobeNewswire

Feb 04, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesKYTX - PR Newswire

Feb 04, 2025

Class Action Filed Against Kyverna Therapeutics, Inc. - GlobeNewswire

Feb 04, 2025

INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire

Feb 04, 2025

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - PR Newswire

Feb 04, 2025

KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Feb 04, 2025

Final Deadline for the Kyverna Therapeutics, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsKYTX - PR Newswire

Feb 04, 2025

KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) DEADLINE ALERT: - GlobeNewswire

Feb 04, 2025

Feb 03, 2025

Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) - openPR

Feb 03, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Feb 03, 2025

KYVERNA THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc.KYTX - Business Wire

Feb 03, 2025

2025-02-03 | KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Kyverna Therapeutics, Inc. to Contact the Firm Today! | NDAQ:KYTX | Press Release - Stockhouse Publishing

Feb 03, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 13.9% in January - MarketBeat

Feb 03, 2025

The Gross Law Firm Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineKYTX - PR Newswire

Feb 03, 2025

Shareholders that lost money on Kyverna Therapeutics, - GlobeNewswire

Feb 03, 2025

Feb 02, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - GlobeNewswire

Feb 02, 2025

2025-02-02 | KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:KYTX | Press Release - Stockhouse Publishing

Feb 02, 2025

Jan 31, 2025

KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ky - PR Newswire

Jan 31, 2025

KYTX DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, - GlobeNewswire

Jan 31, 2025

KYTX Shareholder Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire

Jan 31, 2025

Jan 30, 2025

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - PR Newswire

Jan 30, 2025

Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire

Jan 30, 2025

Deadline Alert: Kyverna Therapeutics, Inc. (KYTX) Investors - GlobeNewswire

Jan 30, 2025

Deadline Alert: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact Glancy Prongay & - EIN News

Jan 30, 2025

Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before February 7, 2025 to Discuss Your RightsKYTX - PR Newswire

Jan 30, 2025

KYVERNA THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire

Jan 30, 2025

Jan 29, 2025

Kyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your ... - The Bakersfield Californian

Jan 29, 2025

Jan 28, 2025

KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - GlobeNewswire Inc.

Jan 28, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure ... - The Hastings Tribune

Jan 28, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna - GlobeNewswire

Jan 28, 2025